An Open-label Trial of Oral Selegiline 5 or 10 mg and Tadalafil 2.5mg Co-administration to Male Patients With Parkinson's Disease and Moderate Erectile Dysfunction
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Selegiline (Primary) ; Tadalafil (Primary)
- Indications Erectile dysfunction; Parkinson's disease
- Focus Therapeutic Use
- 18 Dec 2017 Planned End Date changed from 1 Jan 2016 to 1 Jan 2019.
- 18 Dec 2017 Planned primary completion date changed from 1 Jan 2016 to 1 Dec 2018.
- 23 Apr 2015 Planned End Date changed from 1 Dec 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov record.